KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Free Cash Flow (2016 - 2026)

Neogenomics filings provide 17 years of Free Cash Flow readings, the most recent being -$13.1 million for Q1 2026.

  • On a quarterly basis, Free Cash Flow rose 55.96% to -$13.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $20.2 million, a 162.96% increase, with the full-year FY2025 number at $3.5 million, down 41.51% from a year prior.
  • Free Cash Flow hit -$13.1 million in Q1 2026 for Neogenomics, down from $18.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $38.2 million in Q4 2024 to a low of -$37.3 million in Q1 2022.
  • Median Free Cash Flow over the past 5 years was -$1.6 million (2024), compared with a mean of -$4.3 million.
  • Biggest five-year swings in Free Cash Flow: plummeted 28982.95% in 2022 and later skyrocketed 1620.76% in 2025.
  • Neogenomics' Free Cash Flow stood at $21.0 million in 2022, then fell by 15.13% to $17.8 million in 2023, then skyrocketed by 114.77% to $38.2 million in 2024, then crashed by 50.94% to $18.8 million in 2025, then crashed by 170.0% to -$13.1 million in 2026.
  • The last three reported values for Free Cash Flow were -$13.1 million (Q1 2026), $18.8 million (Q4 2025), and $570000.0 (Q3 2025) per Business Quant data.